These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 12433366)
1. Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. Choi EY; Christianson GJ; Yoshimura Y; Sproule TJ; Jung N; Joyce S; Roopenian DC Immunity; 2002 Nov; 17(5):593-603. PubMed ID: 12433366 [TBL] [Abstract][Full Text] [Related]
2. Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D. Cerwenka A; O'Callaghan CA; Hamerman JA; Yadav R; Ajayi W; Roopenian DC; Joyce S; Lanier LL J Immunol; 2002 Apr; 168(7):3131-4. PubMed ID: 11907062 [TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. Choi EY; Yoshimura Y; Christianson GJ; Sproule TJ; Malarkannan S; Shastri N; Joyce S; Roopenian DC J Immunol; 2001 Apr; 166(7):4370-9. PubMed ID: 11254691 [TBL] [Abstract][Full Text] [Related]
4. EAE tolerance induction with Hsp70-peptide complexes depends on H60 and NKG2D activity. Galazka G; Jurewicz A; Orlowski W; Stasiolek M; Brosnan CF; Raine CS; Selmaj K J Immunol; 2007 Oct; 179(7):4503-12. PubMed ID: 17878346 [TBL] [Abstract][Full Text] [Related]
5. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. O'Callaghan CA; Cerwenka A; Willcox BE; Lanier LL; Bjorkman PJ Immunity; 2001 Aug; 15(2):201-11. PubMed ID: 11520456 [TBL] [Abstract][Full Text] [Related]
6. Subdominant H60 antigen-specific CD8 T-cell response precedes dominant H4 antigen-specific response during the initial phase of allogenic skin graft rejection. Yoo KI; Jeon JY; Ryu SJ; Nam G; Youn H; Choi EY Exp Mol Med; 2015 Feb; 47(2):e140. PubMed ID: 25676063 [TBL] [Abstract][Full Text] [Related]
7. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879 [TBL] [Abstract][Full Text] [Related]
8. The molecular and functional characterization of a dominant minor H antigen, H60. Malarkannan S; Shih PP; Eden PA; Horng T; Zuberi AR; Christianson G; Roopenian D; Shastri N J Immunol; 1998 Oct; 161(7):3501-9. PubMed ID: 9759870 [TBL] [Abstract][Full Text] [Related]
10. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Choi EY; Christianson GJ; Yoshimura Y; Jung N; Sproule TJ; Malarkannan S; Joyce S; Roopenian DC Blood; 2002 Dec; 100(13):4259-65. PubMed ID: 12393464 [TBL] [Abstract][Full Text] [Related]
11. Primary vascularization of the graft determines the immunodominance of murine minor H antigens during organ transplantation. Kwun J; Malarkannan S; Burlingham WJ; Knechtle SJ J Immunol; 2011 Oct; 187(8):3997-4006. PubMed ID: 21900176 [TBL] [Abstract][Full Text] [Related]
12. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response]. Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545 [TBL] [Abstract][Full Text] [Related]
13. NKG2D-independent suppression of T cell proliferation by H60 and MICA. Kriegeskorte AK; Gebhardt FE; Porcellini S; Schiemann M; Stemberger C; Franz TJ; Huster KM; Carayannopoulos LN; Yokoyama WM; Colonna M; Siccardi AG; Bauer S; Busch DH Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11805-10. PubMed ID: 16091471 [TBL] [Abstract][Full Text] [Related]
14. Expression of NKG2D and its ligand in mouse heart allografts may have a role in acute rejection. Feng L; Ke N; Ye Z; Guo Y; Li S; Li Q; Li Y Transplant Proc; 2009 Dec; 41(10):4332-9. PubMed ID: 20005394 [TBL] [Abstract][Full Text] [Related]
15. H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect. Choi EY; Choi K; Nam G; Kim W; Chung M Front Immunol; 2020; 11():1163. PubMed ID: 32587590 [TBL] [Abstract][Full Text] [Related]
16. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Diefenbach A; Hsia JK; Hsiung MY; Raulet DH Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935 [TBL] [Abstract][Full Text] [Related]
17. Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens. Yin L; Poirier G; Neth O; Hsuan JJ; Totty NF; Stauss HJ Int Immunol; 1993 Sep; 5(9):1003-9. PubMed ID: 7694638 [TBL] [Abstract][Full Text] [Related]
19. Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D. Takada A; Yoshida S; Kajikawa M; Miyatake Y; Tomaru U; Sakai M; Chiba H; Maenaka K; Kohda D; Fugo K; Kasahara M J Immunol; 2008 Feb; 180(3):1678-85. PubMed ID: 18209064 [TBL] [Abstract][Full Text] [Related]
20. The immunogenomics of minor histocompatibility antigens. Roopenian D; Choi EY; Brown A Immunol Rev; 2002 Dec; 190():86-94. PubMed ID: 12493008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]